Your institution may have access to this item. Find your institution then sign in to continue.
Title
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
Authors
Smolen, J; Landewé, R B; Mease, P; Brzezicki, J; Mason, D; Luijtens, K; van Vollenhoven, R F; Kavanaugh, A; Schiff, M; Burmester, G R; Strand, V; Vencovsky, J; van der Heijde, D
Abstract
Certolizumab pegol is a PEGylated tumour necrosis factor inhibitor.
Publication
Annals of the rheumatic diseases, 2009, Vol 68, Issue 6, p797